HER-2/neu and topoisomerase IIα gene amplification and protein expression in invasive breast carcinomas -: Chromogenic in situ hybridization and immunohistochemical analyses

被引:43
作者
Bhargava, R [1 ]
Lal, P [1 ]
Chen, BY [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA
关键词
HER-2/neu; topoisomerase II alpha; chromogenic in situ hybridization; CISH; amplification; overexpression; breast carcinoma;
D O I
10.1309/PCFK8YTQPYWD534F
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We studied HER-2/neu (HER-2) and topoisomerase Ha (topo2a) amplification (using chromogenic in situ hybridization) and overexpression (immunohistochemical analysis) in 113 invasive breast carcinomas. A gene copy number/chromosome 17 copy number ratio of 2.0 or higher indicated amplification. A topo2a/chromosome 17 ratio of less than 0.8 indicated gene deletion. HER-2 overexpression was scored according to standard Hercep Test guidelines (DAKO, Carpinteria, CA). Overexpression of topo2a was identified when nuclear staining was found in more than 5% of tumor cells. Of 113 tumors, 104 were analyzed successfully for HER-2 and topo2a amplification. Of the 104, 64 showed HER-2 amplification; 25 of these (39%) also showed topo2a amplification. No amplification was found in 40 tumors. Deletion of topo2a was seen in 7 (11%) of 64 HER-2-amplified tumors and 2 (5%) of 40 nonamplified tumors. Of 25 tumors with topo2a amplification, 18 (72%) overexpressed topo2a. Only 3 (4%) of 79 tumors without topo2a amplification overexpressed topo2a. Amplification of topo2a is associated with HER-2 amplification but not vice versa. Amplification of topo2a resulted in protein overexpression in 72% of tumors, but topo2a overexpression rarely occurred without gene amplification. Identification of topo2a and HER-2 status might have therapeutic and prognostic implications.
引用
收藏
页码:889 / 895
页数:7
相关论文
共 26 条
  • [11] Amplification and deletion of topoisomerase IIα associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer
    Järvinen, TAH
    Tanner, M
    Rantanen, V
    Bärlund, M
    Borg, Å
    Grénman, S
    Isola, J
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (03) : 839 - 847
  • [12] Tissue microarray technology for high-throughput molecular profiling of cancer
    Kallioniemi, OP
    Wagner, U
    Kononen, J
    Sauter, G
    [J]. HUMAN MOLECULAR GENETICS, 2001, 10 (07) : 657 - 662
  • [13] Tissue microarrays for high-throughput molecular profiling of tumor specimens
    Kononen, J
    Bubendorf, L
    Kallioniemi, A
    Bärlund, M
    Schraml, P
    Leighton, S
    Torhorst, J
    Mihatsch, MJ
    Sauter, G
    Kallioniemi, OP
    [J]. NATURE MEDICINE, 1998, 4 (07) : 844 - 847
  • [14] Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples
    Mueller, RE
    Parkes, RK
    Andrulis, I
    O'Malley, FP
    [J]. GENES CHROMOSOMES & CANCER, 2004, 39 (04) : 288 - 297
  • [15] Pegram MD, 2000, SEMIN ONCOL, V27, P21
  • [16] Penault-Llorca F, 2003, INT J ONCOL, V22, P1319
  • [17] Interstitial deletions and intrachromosomal amplification initiated from a double-strand break targeted to a mammalian chromosome
    Pipiras, E
    Coquelle, A
    Bieth, A
    Debatisse, M
    [J]. EMBO JOURNAL, 1998, 17 (01) : 325 - 333
  • [18] Simplification of DNA topology below equilibrium values by type II topoisomerases
    Rybenkov, VV
    Ullsperger, C
    Vologodskii, AV
    Cozzarelli, NR
    [J]. SCIENCE, 1997, 277 (5326) : 690 - 693
  • [19] Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
    Seidman, AD
    Fornier, MN
    Esteva, FJ
    Tan, L
    Kaptain, S
    Bach, A
    Panageas, KS
    Arroyo, C
    Valero, V
    Currie, V
    Gilewski, T
    Theodoulou, M
    Moynahan, ME
    Moasser, M
    Sklarin, N
    Dickler, M
    D'Andrea, G
    Cristofanilli, M
    Rivera, E
    Hortobagyi, GN
    Norton, L
    Hudis, CA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) : 2587 - 2595
  • [20] Tissue microarrays: A powerful tool for high-throughput analysis of clinical specimens - A review of the method with validation data
    Skacel, M
    Skilton, B
    Pettay, JD
    Tubbs, RR
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2002, 10 (01): : 1 - 6